# US 2025/0032587 A1 · Novel Polymeric hGH Prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0032587 A1
- Document ID: US20250032587A1
- Status: Published application
- Kind: A1
- Application number: 18/891,744
- Filed: 2024-09-20
- Published: 2025-01-30
- Earliest claimed: 2014-11-18
- Assignees: Ascendis Pharma Endocrinology Division A/S
- Applicants: Ascendis Pharma Endocrinology Division A/S
- Inventors: Thomas Kurpiers; Harald Rau; Evelyn Exner; Steen Jensen; Grethe Nørskov Rasmussen; Torben Lessmann; Thomas Wegge; Alina Hermann; Nina Schubert; Anna Splanemann; Joachim Zettler
- Web page: https://patentgrep.com/patent/US20250032587A1

## CPC

- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A01G 2/00: Vegetative propagation (plant reproduction by tissue culture techniques A01H4/00)
- A01G 17/005: {Cultivation methods}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08G 65/3348: {containing nitrogen in addition to sulfur}
- C08G 2650/06: Epoxy-capping
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01G: HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING (picking of fruits, vegetables, hops or the like A01D46/00; propagating unicellular algae C12N1/12)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A liquid pharmaceutical formulation comprising 9 to 150 mg/mL of a polymeric human growth hormone (hGH) prodrug or a pharmaceutically acceptable salt thereof of formula (Ia) or (Ib)
wherein
-D is a hGH moiety connected to the rest of the molecule through an amine functional group;
n is 0, 1, 2, 3, or 4;
—X— is a chemical bond or a spacer;
═Y1 is selected from the group consisting of ═O and ═S;
—Y2— is selected from the group consisting of —O— and —S—;
—Y3—, —Y5— are independently of each other selected from the group consisting of —O— and —S—;
—Y4— is selected from the group consisting of —O—, —NR5— and —C(R6R6a)—;
—R1 is a water-soluble PEG-based moiety comprising at least 40% PEG having a molecular weight ranging from 30 to 50 kDa;
—R2, —R3, —R5, —R6, —R6a are independently of each other selected from the group consisting of —H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
—R4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
—W— is selected from the group consisting of C1-20 alkyl optionally interrupted by one or more groups selected from the group consisting of C3-10 cycloalkyl, 8- to 30-membered carbopolycyclyl, 3- to 10-membered heterocyclyl, —C(O)—, —C(O)N(R7)—, —O—, —S— and —N(R7)—;
-Nu is a nucleophile selected from the group consisting of —N(R7R7a), —N(R7OH), —N(R7)—N(R7aR7b), —S(R7), —COOH,
—Ar— is selected from the group consisting of
wherein
dashed lines indicate attachment to the rest of the prodrug,
—Z1— is selected from the group consisting of —O—, —S— and —N(R7)—, and
—Z2— is —N(R7)—; and
—R7, —R7a, —R7b are independently of each other selected from the group consisting of —H, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl;
wherein the prodrug of formula (Ia) and (Ib) is optionally further substituted.

### Claim 21 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein —R1 comprises a moiety of formula (II)
wherein
—BP1<, —BP2<, —BP3< are independently of each other selected from the group consisting of —N< and —C(R8)<;
R8 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl;
P1, —P2, —P3, —P4 are independently of each other a PEG-based chain comprising at least 40% PEG and having a molecular weight ranging from 8 to 12 kDa;
—C1—, —C2— are independently of each other selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more R9, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R10)—, —S(O)2N(R10)—,
—S(O)N(R10)—, —S(O)2—, —S(O)—, —N(R10)S(O)2N(R10a)—, —S—,
—N(R10)—, —OC(OR10)(R10a)—, —N(R10)C(O)N(R10a)—, and —OC(O)N(R10)—;
each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more R9, which are the same or different;
each R9 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COOR11, —OR11, —C(O)R11, —C(O)N(R11R11a), —S(O)2N(R11R11a),
—S(O)N(R11R11a), —S(O)2R11, —S(O)R11, —N(R11)S(O)2N(R11aR11b), —SR11,
—N(R11R11a), —NO2, —OC(O)R11, —N(R11)C(O)R11a, —N(R11)S(O)2R11a,
—N(R11)S(O)R11a, —N(R11)C(O)OR11a, —N(R11)C(O)N(R11aR11b),
—OC(O)N(R11R11a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and
each R10, R10a, R11, R11a and R11b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.

### Claim 22 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein —R1 comprises a moiety of formula (IIc):
wherein
p1, p2, p3, p4 are independently an integer ranging from 180 to 270, preferably from 200 to 250, even more preferably from 210 to 240 and most preferably from 220 to 240.

### Claim 23 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the polymeric hGH prodrug is of formula (IV)
wherein
D is a hGH moiety connected to the rest of the molecule through an amine functional group; and
p1, p2, p3, p4 are independently an integer ranging from 180 to 270, preferably from 200 to 250, even more preferably from 210 to 240 and most preferably from 220 to 240.

### Claim 24 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises at least one excipient.

### Claim 25 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises at least one buffering agent.

### Claim 26 (depends on 25)

The liquid pharmaceutical formulation of claim 25, wherein the at least one buffering agent is selected from the group consisting of sodium phosphate, bicarbonate, succinate, histidine, citrate and acetate.

### Claim 27 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises from 15 to 120 mg/mL, 30 to 45 mg/mL, 75 to 105 mg/mL, 42 mg/mL or 84 mg/mL of the polymeric hGH prodrug.

### Claim 28 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
9-150
mg/ml
succinic acid
5-50
mM
optionally trehalose dihydrate
50-90
mg/ml
optionally methionine
1-50
mg/ml
and has a pH ranging from pH 4.0 to pH 6.0 which is titrated using a suitable buffer.

### Claim 29 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
15-120
mg/ml
succinic acid
5-40
mM
optionally trehalose dihydrate
60-86
mg/ml
optionally methionine
5-40
mM
and has a pH ranging from pH 4.0 to pH 6.0 which is titrated using a suitable buffer.

### Claim 30 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
30-45
mg/ml
succinic acid
5-20
mM
optionally trehalose dihydrate
75-86
mg/ml
optionally methionine
5-20
mM
and has a pH ranging from pH 4.5 to pH 5.5 which is titrated using a suitable buffer.

### Claim 31 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
75-105
mg/ml
succinic acid
5-20
mM
optionally trehalose dihydrate
60-81
mg/ml
optionally methionine
5-20
mM
and has a pH ranging from pH 4.5 to pH 5.5 which is titrated using a suitable buffer.

### Claim 32 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
42
mg/ml
succinic acid
10
mM
optionally trehalose dihydrate
79-86
mg/ml
optionally methionine
10
mM
and has a pH ranging from pH 4.5 to pH 5.5 which is titrated using a suitable buffer.

### Claim 33 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises:
polymeric hGH prodrug
84
mg/ml
succinic acid
10
mM
optionally trehalose dihydrate
70-80
mg/ml
optionally methionine
10
mM
and has a pH ranging from pH 4.5 to pH 5.5 which is titrated using a suitable buffer.

### Claim 34 (depends on 20)

The liquid pharmaceutical formulation of claim 20, wherein the formulation comprises at least one further biologically active agent.

### Claim 35 (depends on 20)

A method of treating, controlling, delaying, or preventing in a mammalian patient in need of the treatment, control, delay, or prevention of at least one disease, which can be treated, controlled, delayed, or prevented with hGH, wherein the method comprises:
a step of administering to the patient a therapeutically effective amount of the liquid pharmaceutical formulation of claim 20.

### Claim 36 (depends on 35)

The method of claim 35, wherein the administration is via topical, enteral, or parenteral administration, or is by external application, injection, or infusion, direct delivery to the brain via implanted device allowing delivery to brain tissue or brain fluids, direct intracerebroventricular injection or infusion, injection or infusion into brain or brain associated regions, injection into the subchoroidal space, retro-orbital injection, or ocular instillation.

### Claim 37 (depends on 35)

The method of claim 35, wherein the administration is by intraarticular, periarticular, intradermal, subcutaneous, intramuscular, intravenous, intraosseous, intraperitoneal, intrathecal, intracapsular, intraorbital, intravitreal, intratympanic, intravesical, intracardiac, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intraventricular, or infrasternal injection or infusion.

### Claim 38 (depends on 35)

The method of claim 35, wherein the disease is selected from the group consisting of growth hormone deficiency in children, idiopathic short stature, short stature homeobox gene mutations, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, children born small for gestational age, chronic renal insufficiency, growth hormone deficiency in adults, wasting due to HIV or AIDS or other malignancy, short bowel syndrome, sarcopenia, and frailty.

### Claim 39 (depends on 35)

The method of claim 35, wherein the disease is growth hormone deficiency in children.

### Claim 40 (depends on 16)

The method of claim 16, wherein the disease is growth hormone deficiency in adults.
